Dapagliflozin, which functions primarily by blocking glucose reabsorption in the proximal tubule by targeting sodium-glucose cotransporter 2 (SGLT2), is a hypoglycemic agent used in the clinic to treat diabetes. This evidence concerns the gene SLC5A2 and diabetes mellitus.